Cited by 756Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Open access

Meyers, Paul A., Schwartz, Cindy L., Krailo, Mark D., Healey, John H., Bernstein, Mark L., Betcher, Donna, Ferguson, William S., Gebhardt, Mark C., Goorin, Allen M., Harris, Michael, Kleinerman, Eugenie, Link, Michael P., Nadel, Helen, Nieder, Michael, Siegal, Gene P., Weiner, Michael A., Wells, Robert J., Womer, Richard B., Grier, Holcombe E.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2008.14.0095

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma. Patients and Methods: Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 × 2 factorial design. The primary end points for analysis were EFS and overall survival. Results: In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP (P = .08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03). The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96). Conclusion: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.14.0095

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,034
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Self-citation
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citation
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citation
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
Souhami, R. L., Craft, A. W., van der Eijken, J. W., Nooij, M. A., Spooner, D. A., Bramwell, V. H. C., Wierzbicki, R. F., MALCOLM, A. J., Kirkpatrick, A., Uscinska, B., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 381

Show all 20 references

Sorted by citations

Items 301–400 of 756

Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
Das, S., Idate, R., Regan, D. P., Fowles, J. S., Lana, S. E., Thamm, D. H., Gustafson, D. L., & Duval, D. L. (2021) · Communications Biology · doi:10.1038/s42003-021-02683-0 · Cited by 30
Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?
Davies, J. E., Neidle, S., & Taylor, D. G. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.544 · Cited by 28
In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma
Zhang, Z., Liu, J., Shao, Z.-W., Pu, F., Wang, B.-C., Wu, Q., Zhang, Y., Zeng, X., Guo, X., Yang, S., et al. (2017) · Medicine · doi:10.1097/md.0000000000007245 · Cited by 28
The evolution of systemic therapy in sarcoma
Constantinidou, A., Pollack, S. M., Loggers, E. T., Rodler, E. T., & Jones, R. L. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.161 · Cited by 27
Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas
Castillo‐Ecija, H., Pascual‐Pasto, G., Pérez‐Jaume, S., Resa‐Pares, C., Vilà-Ubach, M., Monterrubio, C., Jimenez‐Cabaco, A., Baulenas‐Farres, M., Muñoz‐Aznar, O., Salvador, N., et al. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.210 · Cited by 27
Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy
Tenardi, R. D., Frühwald, M. C., Jürgens, H., Hertroijs, D. F. L., & Bauer, J. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24001 · Cited by 27
Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials
Wang, X., Zheng, H., Shou, T., Tang, C., Miao, K., & Wang, P. (2017) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-017-0544-9 · Cited by 27
Using Canine Osteosarcoma as a Model to Assess Efficacy of Novel Therapies: Can Old Dogs Teach Us New Tricks?
Rodriguez, C. O. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_13 · Cited by 27
How can survival be improved in localized osteosarcoma?
Jeon, D., & Song, W. S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.79 · Cited by 27
Transcription factor Snai1-1 induces osteosarcoma invasion and metastasis by inhibiting E-cadherin expression
Yang, H., ZHANG, Y., Zhou, Z., Jiang, X., & Shen, A. (2014) · Oncology Letters · doi:10.3892/ol.2014.2079 · Cited by 26
Pediatric Solid Tumors
Dome, J. S., Galindo, C. R., Spunt, S. L., & Santana, V. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00092-x · Cited by 29
LncRNA BLACAT1 accelerates the proliferation and migration of osteosarcoma cells through regulating STAT3
Zhou, D., & Wang, Y. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.01.017 · Cited by 25
Tumor-Infiltrating Lymphocytes as a Feasible Adjuvant Immunotherapy for Osteosarcoma with a Poor Response to Neoadjuvant Chemotherapy
Shi, J., Li, M., & Yang, R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0107 · Cited by 25
Current approaches to management of bone sarcoma in adolescent and young adult patients
Ingley, K. M., Maleddu, A., Grange, F. L., Gerrand, C., Bleyer, A., Yasmin, E., Whelan, J., & Strauss, S. J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29442 · Cited by 26
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Nakano, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073540 · Cited by 25
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial
van den Berg, H., Paulussen, M., Teuff, G. L., Judson, I. R., Gelderblom, H. A. J., Dirksen, U., Brennan, B. M. D., Whelan, J. S., Ladenstein, R. L., Marec‐Bérard, P., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.123 · Cited by 26
Re-calculating! Navigating through the osteosarcoma treatment roadblock
McGuire, J., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.004 · Cited by 26
WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP‐14 pathway
Wang, X., Zhao, X., Yi, Z., Ma, B., Wang, H., Pu, Y., Wang, J., & Wang, S. (2018) · Cell Biology International · doi:10.1002/cbin.10936 · Cited by 26
Targeted Therapies in Bone Sarcomas
Scotlandi, K., Picci, P., & Kovar, H. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789760410 · Cited by 26
Evaluation of eIF4E Expression in an Osteosarcoma-Specific Tissue Microarray
Osborne, T. S., Ren, L., Healey, J. H., Shapiro, L., Chou, A. J., Gorlick, R. G., Hewitt, S. M., & Khanna, C. (2011) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318223d0c1 · Cited by 25
Self-citation
The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma
Zhou, X., Yuan, B., Yuan, W., Wang, C., Gao, R., & Wang, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-1825-0 · Cited by 25
Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases
Huang, G., Nishimoto, K., Yang, Y., & Kleinerman, E. S. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_11 · Cited by 26
Self-citation
Liposomal therapies in oncology: does one size fit all?
Sousa, I., Rodrigues, F., Prazeres, H., Lima, R. T., & Soares, P. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3668-7 · Cited by 25
Immune dysregulation and osteosarcoma: Staphylococcus aureus downregulates TGF‐β and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma
Tuohy, J. L., Somarelli, J. A., Borst, L. B., Eward, W. C., Lascelles, B. D. X., & Fogle, J. E. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12529 · Cited by 25
Immunotherapy in Pediatric Solid Tumors—A Systematic Review
Marayati, R., Quinn, C. H., & Beierle, E. A. (2019) · Cancers · doi:10.3390/cancers11122022 · Cited by 27
CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma
Iwata, S., Tatsumi, Y., Yonemoto, T., Araki, A., Itami, M., Kamoda, H., Tsukanishi, T., Hagiwara, Y., Kinoshita, H., Ishii, T., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8086 · Cited by 25
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
Livingston, J. A., Hess, K. R., Naing, A., Hong, D. S., PATEL, S. R., Benjamin, R. S., Ludwig, J. A., Conley, A. P., Herzog, C. E., Anderson, P. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10910 · Cited by 25
Chemotherapy in Nonmetastatic Osteosarcoma: Recent Advances and Implications for Developing Countries
Rastogi, S., Aggarwal, A., Tiwari, A., & Sharma, V. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.007336 · Cited by 25
Microenvironmental Targets in Sarcoma
Ehnman, M., & Larsson, O. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00248 · Cited by 24
Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
Wang, G., Cao, L., Jiang, Y., Zhang, T., Wang, H., Wang, Z., Xu, J., Mao, M., Hua, Y., Cai, Z., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.798837 · Cited by 24
Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents
Meazza, C., Luksch, R., Daolio, P. A., Podda, M. G., Luzzati, A., Gronchi, A., Parafioriti, A., Gandola, L., Collini, P., Ferrari, A., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0875-x · Cited by 23
Variability in the reported management of pulmonary metastases in osteosarcoma
Bhattasali, O., Vo, A. T., Roth, M. E., Geller, D., Randall, R. L., Gorlick, R. G., & Gill, J. B. (2015) · Cancer Medicine · doi:10.1002/cam4.407 · Cited by 24
Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro
Geiß, C., Kis, Z., Leuchs, B., Frank-Stöhr, M., Schlehofer, J. R., Rommelaere, J., Dinsart, C., & Lacroix, J. (2017) · Viruses · doi:10.3390/v9100301 · Cited by 24
Pegfilgrastim for prevention of chemotherapy‐associated neutropenia in pediatric patients with solid tumors
Borinstein, S. C., Pollard, J. A., Winter, L., & Hawkins, D. S. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22086 · Cited by 24
Medical Application of Liposomes
Basu, B., Prajapati, B. G., Dutta, A., & Paliwal, H. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00002 · Cited by 24
Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets
Castillo‐Tandazo, W., Mutsaers, A. J., & Walkley, C. R. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00534-w · Cited by 23
Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis
Johal, S., Ralston, S., & Knight, C. (2013) · Value in Health · doi:10.1016/j.jval.2013.08.2294 · Cited by 23
The Efficacy of Abraxane on Osteosarcoma Xenografts in Nude Mice and Expression of Secreted Protein, Acidic and Rich in Cysteine
Yang, Y., Niu, X., Zhang, Q., Hao, L., Ding, Y., & Xu, H. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31823e62e5 · Cited by 23
The histone deacetylase inhibitor entinostat/syndax 275 in osteosarcoma
Kiany, S., Harrison, D., & Gordon, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_7 · Cited by 24
In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma
He, Y.-T., Zhang, Q.-M., Kou, Q.-C., & Tang, B. (2016) · Oncology Letters · doi:10.3892/ol.2016.4714 · Cited by 22
Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group
Hiraga, H., & Ozaki, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab120 · Cited by 22
To Market, To Market—2010
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00002-3 · Cited by 22
SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression
Lézot, F., Corre, I., Morice, S., Rédiní, F., & Verrecchia, F. (2020) · Cells · doi:10.3390/cells9030536 · Cited by 22
Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research
Bozorgi, A., & Sabouri, L. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100324 · Cited by 22
Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1
Xiao, W., Wu, H., Li, W., Zhang, M., Zhu, S., & Zhang, D. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.191635 · Cited by 22
Biomaterials‐Boosted Immunotherapy for Osteosarcoma
Sun, C., Li, S., & Ding, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400864 · Cited by 25
Immunotherapy in Sarcoma: Future Horizons
Burgess, M. A., Gorantla, V. C., Weiss, K. R., & Tawbi, H. A. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0476-7 · Cited by 21
Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency
Iwicka, E., Hajtuch, J., Dzierzbicka, K., & Inkielewicz‐Stępniak, I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.970967 · Cited by 21
Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells
Wang, T.-K., Lin, Y.-M., Lo, C., Tang, C., Teng, C. J., Chao, W., Wu, M. H., Liu, C., & Hsieh, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4661-y · Cited by 21
Recent advances in understanding osteosarcoma and emerging therapies
Gaspar, N., Costa, M. E. M. D., Fromigué, O., Droit, R., Berlanga, P., & Marchais, A. (2020) · Faculty Reviews · doi:10.12703/r/9-18 · Cited by 22
SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013
Redondo, A., Cruz, J. J., Pousa, A. L., & Barón, F. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1087-0 · Cited by 21
Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis – a systematic literature review
Smolle, M. A., Szkandera, J., Andreou, D., Palmerini, E., Bergovec, M., & Leithner, A. (2020) · EFORT Open Reviews · doi:10.1302/2058-5241.5.200069 · Cited by 19
Identification and Development of a Novel 4-Gene Immune-Related Signature to Predict Osteosarcoma Prognosis
Cao, M., Zhang, J., Xu, H., Lin, Z., Chang, H., Wang, Y., Huang, X., Chen, X., Wang, H., & Song, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.608368 · Cited by 20
Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model
Le, T., Su, S., & Shahriyari, L. (2021) · Cells · doi:10.3390/cells10082009 · Cited by 22
A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages
Richert, I., BERCHARD, P., Abbes, L., Novikov, A., Chettab, K., Vandermoeten, A., Dumontet, C., Karanian, M., Kerzerho, J., Caroff, M., et al. (2023) · Cancers · doi:10.3390/cancers15184635 · Cited by 22
A role for maintenance therapy in managing sarcoma
Ray-Coquard, I. L., & Cesne, A. L. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.003 · Cited by 20
Osteosarcoma: Time to move on?
Bielack, S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.009 · Cited by 20
Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance
WANG, J., & Li, G. (2014) · Oncology Letters · doi:10.3892/ol.2014.2773 · Cited by 20
Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species
Davis, L. E., Jeng, S., Svalina, M. N., Huang, E., Pittsenbarger, J., Cantor, E. L., Berlow, N., Séguin, B., Mansoor, A., McWeeney, S. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19532 · Cited by 19
Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients
Bhuvaneshwar, K., Harris, M. A., Gusev, Y., Madhavan, S., Iyer, R. K., Vilboux, T., Deeken, J. F., Yang, E., & Shankar, S. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5474-y · Cited by 19
Self-citation
Targeting tumor microenvironment and metastasis in children with solid tumors
Wessel, K. M., & Kaplan, R. N. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001082 · Cited by 20
Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments
Winstone, J., Chadda, S., Ralston, S., & Sajosi, P. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0349-z · Cited by 19
Immune-based therapeutics for pediatric cancer
Capitini, C. M., Mackall, C. L., & Wayne, A. S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903431022 · Cited by 19
Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma
Xiao, X., Wang, W., Zhang, H., Gao, P., Fan, B., Huang, C., Fu, J., Chen, G., Shi, L., Zhu, H., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2853-5 · Cited by 19
Comparative Outcome of Thai Pediatric Osteosarcoma Treated with Two Protocols: the Role of High-Dose Methotrexate (HDMTX) in a Single Institute Experience
Choeyprasert, W., Pakakasama, S., Sirachainan, N., Songdej, D., Chuansumrit, A., Anurathapan, U., Hongeng, S., & Nartthanarung, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9823 · Cited by 19
Long non-coding RNA CDKN2B-AS1 promotes osteosarcoma by increasing the expression of MAP3K3 via sponging miR-4458
Daokun, G., & Cao, H. (2020) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00415-7 · Cited by 19
New Small Molecules Targeting Apoptosis and Cell Viability in Osteosarcoma
Maugg, D., Rothenaigner, I., Schorpp, K., Potukuchi, H. K., Korsching, E., Baumhoer, D., Hadian, K., Smida, J., & Nathrath, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129058 · Cited by 19
Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.
Zheng, S., Zhou, S., Qiao, G., Yang, Q., Zhang, Z., Lin, F., Min, D., Tang, L., Li, H., Sun, Y., et al. (2015) · Europe PMC (PubMed Central) · Cited by 19
Osteosarcoma of the Pelvis: A Monoinstitutional Experience in Patients Younger than 41 Years
Ferrari, S., Palmerini, E., Fabbri, N., Staals, E. L., Ferrari, C., Alberghini, M., & Picci, P. (2012) · Tumori Journal · doi:10.1177/030089161209800605 · Cited by 19
Is There a Role for Immunotherapy in Osteosarcoma?
Loeb, D. M. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_25 · Cited by 19
A cuproptosis-related genes signature associated with prognosis and immune cell infiltration in osteosarcoma
Yang, W., Wu, H., Tong, L., Wang, Y., Guo, Q., Xu, L., Yan, H., Yin, C., & Sun, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015094 · Cited by 18
Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care
Kumar, R. R., Sporn, K., Khanna, A., Paladugu, P., Gowda, C., Ngo, A., Jagadeesan, R., Zaman, N., & Tavakkoli, A. (2025) · Diagnostics · doi:10.3390/diagnostics15111377 · Cited by 21
Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5′6-Dimethylxanthenone-4-acetic Acid (Vadimezan)
Cheng, G., Sun, J., Fridlender, Z. G., Wang, L. S., Ching, L., & Albelda, S. Μ. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065631 · Cited by 18
Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2
Zhang, C., Zhao, Y., & Zeng, B. (2013) · Cancer Biomarkers · doi:10.3233/cbm-130305 · Cited by 18
Prospective Preliminary In Vitro Investigation of a Magnetic Iron Oxide Nanoparticle Conjugated with Ligand CD80 and VEGF Antibody As a Targeted Drug Delivery System for the Induction of Cell Death in Rodent Osteosarcoma Cells
Kovach, A. K., Gambino, J. M., Nguyen, V., Nelson, Z., Szasz, T. P., Liao, J., Williams, L. N., Bulla, S., & Prabhu, R. K. (2016) · BioResearch open access · doi:10.1089/biores.2016.0020 · Cited by 18
Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy
Dutour, A., Pasello, M., Farrow, L., Amer, M. H., Entz‐Werlé, N., Nathrath, M., Scotlandi, K., Mittnacht, S., & Gomez‐Brouchet, A. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10257-3 · Cited by 21
Early Lymphocyte Recovery and Outcome in Osteosarcoma
Lee, L. H., Lin, F., Pope, J., & Wagner, L. M. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000717 · Cited by 17
Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing’s Sarcoma Tumor Growth
Mullard, M., Cadé, M., Morice, S., Dupuy, M., Danieau, G., Amiaud, J., Renault, S., Lézot, F., Brion, R., Thépault, R., et al. (2020) · Cancers · doi:10.3390/cancers12113438 · Cited by 17
Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network
Bompas, E., Martin, V., Meniai-Merzouki, F., Toulmonde, M., Marec‐Bérard, P., Claude, L., Ducimetière, F., Chargari, C., Minard‐Colin, V., Corradini, N., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.10.009 · Cited by 18
Osteosarcoma: An Evolving Understanding of a Complex Disease
Alexander, J. H., Binitie, O. T., Letson, G. D., & Joyce, D. M. (2021) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-20-00838 · Cited by 17
Resource‐appropriate selection of osteosarcoma treatment protocols in low‐ and middle‐income countries
Mailankody, S., Kumar, V. S., Khan, S. A., Banavali, S. D., & Bajpai, J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29540 · Cited by 16
First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Zhou, Y., Yang, Q., Dong, Y., Ji, T., Zhang, B., Yang, C., Zheng, S., Tang, L., Zhou, C., Qian, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2470 · Cited by 17
Exploring the landscape of immunotherapy approaches in sarcomas
Pilavaki, P., Panagi, M., Arifi, S., Jones, R. L., Stylianopoulos, T., & Constantinidou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1069963 · Cited by 17
Recent progress in canine tumor vaccination: potential applications for human tumor vaccines
Denies, S., & Sanders, N. N. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.104 · Cited by 17
Sarcoma Tumor Microenvironment
Tsagozis, P., Gonzalez‐Molina, J., Georgoudaki, A., Lehti, K., Carlson, J. W., Lundqvist, A., Haglund, F., & Ehnman, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_20 · Cited by 19
Chick Embryo Extract Demethylates Tumor Suppressor Genes in Osteosarcoma Cells
Mu, X., Sultankulov, B., Agarwal, R., Mahjoub, A., Schott, T., Greco, N., Huard, J., & Weiss, K. R. (2013) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-013-3104-6 · Cited by 17
Trps1 is associated with the multidrug resistance of osteosarcoma by regulating MDR1 gene expression
Jia, M., Hu, J., Li, W., Su, P., Zhang, H., Zhang, X., & Zhou, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.01.041 · Cited by 17
Pelvic Bone Sarcomas: Controversies and Treatment Options
Morris, C. D. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0053 · Cited by 17
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
Barnes, D., Dutton, P., Bruland, Ø. S., Gelderblom, H. A. J., Faleti, A., Bühnemann, C., van Maldegem, A. M., Johnson, H., Poulton, L., Love, S., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09697-9 · Cited by 16
Diallyl trisulfide inhibits osteosarcoma 143B cell migration, invasion and EMT by inducing autophagy
Liu, X., Wang, N., He, Z., Chen, C., Ma, J., Liu, X., Deng, S., & Xie, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26681 · Cited by 16
Computer-aided resection and endoprosthesis design for the management of malignant bone tumors around the knee: outcomes of 12 cases
Ding, H., Yu, G.-W., Tu, Q., Liu, B., Shen, J., Wang, H., & Wang, Y. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-331 · Cited by 16
Regulatory effects of microRNA‑184 on osteosarcoma via the Wnt/β‑catenin signaling pathway
Du, Z., Li, F., Wang, L., Huang, H., & Xu, S. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9184 · Cited by 16
Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study
Brard, C., Hampson, L. V., Gaspar, N., Deley, M. L., & Teuff, G. L. (2019) · BMC Medical Research Methodology · doi:10.1186/s12874-019-0714-z · Cited by 16
Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?
Tsuda, Y., Tsoi, K. M., Stevenson, J. D., Parry, M., Fujiwara, T., Sumathi, V. P., & Jeys, L. M. (2020) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000001079 · Cited by 18
Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response
Pratt, H. G., Justin, E. M., & Lindsey, B. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_6 · Cited by 16
Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency
Wiebel, M., Kailayangiri, S., Altvater, B., Meltzer, J., Grobe, K., Kupich, S., & Rössig, C. (2021) · Cancer Reports · doi:10.1002/cnr2.1394 · Cited by 16
Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach
Paiva‐Santos, A. C., Domingues, C., Jarak, I., Veiga, F., & Figueiras, A. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.12.003 · Cited by 18
Novel agents in development for pediatric sarcomas
Hughes, D. P. M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832c94e2 · Cited by 16
How companion animals contribute to the fight against cancer in humans.
Thamm, D. H., & DOW, S. W. (2009) · PubMed · Cited by 16
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma
Taçyıldız, N., Özdemir, S. İ., Ünal, E., Hamamcı, M. B., Dincaslan, H. U., & Yavuz, G. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001236 · Cited by 16

Authors: Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., Kleinerman, E., Link, M. P., Nadel, H., Nieder, M., Siegal, G. P., Weiner, M. A., Wells, R. J., Womer, R. B., & Grier, H. E.
Affiliations: Children's Oncology Group (US)
ORCID: Meyers, Paul A.
Schwartz, Cindy L.
Krailo, Mark D.
Healey, John H.
Bernstein, Mark L.
Ferguson, William S.
Kleinerman, Eugenie
Nadel, Helen
Siegal, Gene P.
Womer, Richard B.
Grier, Holcombe E.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-02-01
Volume: 26
Issue: 4
Pages: 633-638
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.14.0095
OpenAlex: W2103405666
Cited by: 752
References: 20
Citations by year: 2026: 21 · 2025: 30 · 2024: 30 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 70 · 2019: 39 · 2018: 38 · 2017: 55 · 2016: 49 · 2015: 50 · 2014: 57 · 2013: 46 · 2012: 36
FWCI: 33.48
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Children’s Oncology Group
National Institutes of Health (CA98543)
National Cancer Institute (U10CA098543, CA-98543)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: osteosarcoma, muramyl tripeptide, ifosfamide, cisplatin, doxorubicin, methotrexate, event-free survival, overall survival, pediatric cancer chemotherapy, immunomodulatory therapy, surgical resection
MeSH terms: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Doxorubicin, Female, Humans, Ifosfamide, Infant, Lung Neoplasms, Male, Methotrexate, Neoplasm Recurrence, Local, Osteosarcoma, Survival Rate, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks